How a team from closed East Bay biotech Plexxicon is zeroing in on a new cancer target
Opna Bio is backed with $38 million as well as drugs brought over from Plexxikon. |!| San Francisco
Opna Bio is backed with $38 million as well as drugs brought over from Plexxikon. |!| San Francisco